Depakote (divalproex sodium) is a medication with three FDA-approved uses: treating seizures, managing manic episodes in bipolar disorder, and preventing migraines. It works by increasing levels of a calming brain chemical called GABA, which helps stabilize electrical activity in the brain. Beyond these approved uses, doctors also prescribe it off-label for several other conditions.
Seizure Treatment
Depakote is approved to treat several types of epilepsy. It can be used alone or alongside other seizure medications for complex partial seizures, which are episodes where you remain partially conscious but experience altered awareness, unusual movements, or sensory changes. It’s also approved for absence seizures (sometimes called “petit mal” seizures), those brief episodes where a person appears to blank out for a few seconds. For people who have multiple seizure types that include absence seizures, Depakote can be added to an existing medication regimen.
Doctors typically monitor blood levels of the drug during treatment, aiming for a concentration between 50 and 100 mg/L. Keeping levels in this range helps balance seizure control against side effects. Blood draws are routine, especially early in treatment or after dose changes.
Bipolar Disorder
Depakote is approved for treating acute manic or mixed episodes in bipolar disorder. Manic episodes involve periods of abnormally elevated energy, reduced need for sleep, racing thoughts, and impulsive behavior. Mixed episodes combine features of mania and depression at the same time. The standard starting dose for acute mania is 750 mg daily, split into multiple doses, then increased rapidly to reach a therapeutic level.
Many doctors also prescribe Depakote as a long-term maintenance treatment to prevent future manic episodes, though this particular use is technically off-label. The FDA notes there isn’t strong controlled trial data supporting its long-term benefits in bipolar disorder, but it remains widely used for this purpose based on clinical experience and open-label studies.
Migraine Prevention
Depakote is approved for preventing migraines, not for stopping one that’s already started. In a randomized trial published in the journal Neurology, people taking the extended-release form had their monthly migraine count drop by about 1.2 headaches (from a baseline of roughly 4.4 per month), compared to a drop of only 0.6 in the placebo group. That difference is modest but statistically meaningful, and for someone dealing with frequent migraines, even one or two fewer episodes per month can significantly improve quality of life.
This is typically a second- or third-line option. Because of the side effect profile and serious pregnancy risks (more on that below), it’s usually considered after other preventive treatments haven’t worked well enough.
Off-Label Uses
Doctors prescribe Depakote for a number of conditions beyond its approved indications. These include:
- Aggression and impulsivity in people with brain injuries
- Agitation associated with dementia
- Emotional instability and impulsivity in borderline personality disorder
- Adjunctive treatment for schizophrenia, typically added to an antipsychotic
- Alcohol dependence, where some evidence suggests it may help prevent relapse
The evidence behind these off-label uses is generally weaker than for the approved indications, often based on case reports, small studies, or open-label trials rather than large randomized controlled studies. Still, they reflect real clinical practice and can be appropriate when other treatments fall short.
Common Side Effects
The side effects people notice most often are tremor, weight gain, and hair thinning. How frequently these occur depends partly on the dose and the condition being treated. In epilepsy trials using higher doses, tremor affected 57% of patients, hair thinning occurred in 24%, and weight gain showed up in 9%. At lower doses, those numbers dropped to 19%, 13%, and 4% respectively.
In migraine prevention trials, where doses tend to be lower, the rates were more moderate: tremor in 9% of patients, weight gain in 8%, and hair thinning in 7%. By comparison, these side effects occurred in 0% to 2% of people taking a placebo.
Hair thinning is one of the more frustrating side effects for patients and was the single most common reason people stopped treatment in migraine extension studies, with 6% discontinuing because of it. Nausea and vomiting led another 5% to stop, followed by weight gain at 2%.
Serious Safety Risks
Depakote carries three major safety warnings that set it apart from many other medications in its class.
Liver Damage
Fatal liver failure has occurred in people taking Depakote, though it is rare. The risk is highest in children under age two, especially those taking multiple seizure medications or those with underlying metabolic disorders or brain conditions. In older children and adults, the risk drops significantly. Most cases of serious liver injury have occurred within the first six months of treatment, which is why doctors monitor liver function through blood tests during that window.
Pancreatitis
Life-threatening inflammation of the pancreas has been reported in both children and adults. Some cases progressed rapidly from early symptoms to death. This can happen soon after starting the drug or after years of use. Persistent abdominal pain, nausea, vomiting, or loss of appetite while taking Depakote should be evaluated promptly, as these can signal pancreatitis.
Pregnancy and Fetal Harm
This is the most significant concern for women of childbearing age. Depakote is known to cause serious birth defects, including neural tube defects like spina bifida, and these can develop very early in pregnancy, sometimes before a woman even knows she’s pregnant. Beyond structural birth defects, children exposed to Depakote in the womb have lower IQ scores on average and higher rates of autism, ADHD, and hearing impairment.
The American Epilepsy Society’s position is clear: Depakote should not be given to women of childbearing potential unless other treatments have failed. Folic acid supplementation doesn’t appear to reduce the risk of major malformations, though there is some evidence it may partially lower the risk of decreased IQ and autistic traits in exposed children.
How Depakote Differs From Similar Medications
Depakote is the brand name for divalproex sodium, which converts to valproic acid in the body. You may see it referred to interchangeably with “valproate” or “valproic acid” in medical settings. Depakote comes in a delayed-release tablet form, while Depakote ER is an extended-release version designed to be taken once daily. Both contain the same active ingredient but release it at different rates, so the two forms aren’t directly interchangeable at the same dose.
Compared to lithium, the other major mood stabilizer used in bipolar disorder, Depakote tends to be better tolerated in some patients and may work better for mixed episodes and rapid-cycling bipolar disorder. For epilepsy, it competes with a wide range of newer seizure medications that often have fewer side effects but may not be as broadly effective across seizure types.